Ondansetron hydrochloride is under clinical development by Chromocell Therapeutics and currently in Phase II for Chemotherapy Induced Nausea and Vomiting. According to GlobalData, Phase II drugs for Chemotherapy Induced Nausea and Vomiting have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ondansetron hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ondansetron hydrochloride overview
Ondansetron hydrochloride is under development for the treatment of nausea and vomiting in chemotherapy. The drug candidate is administered through sublingual route. It is an anti-emetic therapy and acts as a 5-HT3 antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. The drug is developed based on sublingual spray drug delivery technology platform.
It was also under development for the treatment of post operative nausea and vomiting, radiation induced nausea and vomiting (RINV).
Chromocell Therapeutics overview
Chromocell Therapeutics (Chromocell) discovers and develops flavors, analgesics and drugs for rare diseases. The company is investigating its lead product candidate CC8464 for the treatment of pain from nerve injury, diabetic neuropathy, chemotherapy induced pain, osteoarthritis and visceral pain. It is evaluating programs for pulmonary edema, COPD (chronic obstructive pulmonary disease), cystic fibrosis and other respiratory diseases; and flavor programs to enhance and reduce sweet, bitter, salty, savory, and sour taste sensations and aroma in consumer goods. Chromocell is discovering dietary and nutritional supplements, functional foods and cosmeceuticals. The company utilizes its proprietary Chromovert technology platform to develop drugs by producing multi- and single-subunit sodium voltage-gated channel subtypes. Chromocell is headquartered in North Brunswick, New Jersey, the US.
For a complete picture of Ondansetron hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
